The global distributed control systems market was valued at US$ 17.99 Bn in 2020 and expected to register strong growth, expanding at a CAGR of 4.3% during the forecast period from 2025 to 2033.
The pharmaceutical intermediates market is set to reach from US$ 29,080.8 Mn in 2021 to US$ 41,317.4 Mn by 2033 at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2025 to 2033. Significant rise in drug formulation and research activities and supportive regulatory environment provided by global healthcare agencies will consolidate the pharmaceutical intermediates market during the forecast period.
Polymyositis treatment market projected to grow at a CAGR of 5.9% during the forecast period from 2025 to 2033. Polymyositis is rare connective tissue disease that causes muscle inflammation leading to muscle weakness. According to prevalence studies, globally the incidence of polymyositis is around 1 to 5 per 100,000 individuals and the prevalence is approximately 5 to 22 per 100,000 individuals. Thus, high awareness related to polymyositis diagnosis & treatment, strong drug pipeline, and rising geriatric population expected to assist the growth of polymyositis treatment market in the near future.
Paget’s disease treatment market is projected to grow at a CAGR of 3.4% during the forecast period from 2025 to 2033. Paget’s disease of bone affects the way that bone is renewed & repaired, during this process an uncontrolled level of bone generation occurs that results into an abnormal bone formation. The affected bone is weaker than normal and leads to a bend or deformity making that bone fragile.
Text analytics is an emerging technology in the field of big data analytics targeted to handle unstructured text data. Due to data deluge, there is a huge demand for text analytics from various end user industries, such as BFSI, Healthcare FMCG’s, Telecom, and so on, which is a major driver for the text analytics market.
The paroxysmal nocturnal hemoglobinuria (PNH) is currently valued at US$ 3,163.2 Mn in 2021 and is set to reach US$ 8,380.2 Mn by 2033 projecting stunning growth at a compounded annual growth rate (CAGR) of 11.7% during the forecast period from 2025 to 2033. PNH is a rare disease wherein red blood cells are reported to burst prematurely. It has a global incidence rate of 1.3 cases per million people. The high treatment cost and mortality rate associated with stem cell transplant procedures has increased the popularity of monoclonal antibodies as the most effective treatment molecule for the treatment of PNH.
The neurotrophic keratitis market is set to highlight rapid growth at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2033. Neurotrophic keratitis is an orphan disease which is primarily caused due to the damage of the fifth cranial nerve from the trigeminal nucleus to the nerve endings preset in the eye corneal region. Traditional therapies are employed to suppress the clinical manifestation occurring in different stages of the disease.
The Lambert-Eaton Myasthenic Syndrome (LEMS) market is keen to represent linear growth at a compounded annual growth rate (CAGR) of 6.7% during the forecast period from 2025 to 2033. LEMS is a rare autoimmune disorder which is manifested by the clinical triad which comprises of reduced tendon reflexes, autonomic symptoms and proximal muscle weakness. Most of the patients suffering with LEMS go undiagnosed at an early age due to its overlapping symptoms similar to small cell lung cancer (SCLC).
Alpha thalassemia treatment market accounted for a market value of US$ 643.4 Mn in 2021 and projected to grow at a CAGR of 7.1% during the forecast period from 2025 to 2033. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes.
The global freezing of gait treatment market is growing effectually, expected to grow at a CAGR of 7.2%. Globally, increasing prevalence of Parkinson's disease has significantly increased the revenue of oral dopaminergic medications. FDA approval for new drugs, and promising pipeline products in the equipment and devices segment in the Parkinson's disease industry are driving the overall growth freezing of gait treatment market globally.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.